Based at DCU Invent, Deciphex has gained investors including Inova and GI Partners as it looks to refine its offering for the toxicologic and gastrointestinal segments of pathology.

Deciphex, an Ireland-based automated pathological services provider based at Dublin City University’s Invent incubator, has attracted €2.3m ($2.6m) in a round backed by healthcare provider Inova’s Personalised Health Accelerator. Inova Personalised Health Accelerator was joined in the round by investors including gastroenterology healthcare provider GI Partners of Illinois, angel network Irrus Investments, VC firm ACT Venture Capital and Nextsteps Ventures. Founded in 2017, Deciphex has created an artificial intelligence-powered digital pathology platform called Patholytix that automates basic visual evaluations of biopsy tissue samples so pathologists can dedicate more resources to critical objectives. Deciphex is targeting two branches of pathology with its software – toxicologic projects that investigate tissues for the presence of toxins and poisons, and human gastrointestinal biopsies focused on disease in the body’s digestive organs. The capital will help Deciphex approximately double its headcount to 25 by early 2020 as the company looks to build presence in the market for preclinical toxicologic pathology services. Funds from the round will also fuel continued research and development at Deciphex, which has been working with GI Partners to deliver digital gastrointestinal pathological content for deep learning applications since August 2018. Deciphex closed a funding round of undisclosed size in October 2017 with contributions from unnamed Ireland-based investors from the diagnostics industry.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?